Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360

Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR Formulation

SAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced Dr. Dolly Jacob, Director Integrated Development Services of Quotient Sciences, will present the collaborative work of Ensysce and Quotient Sciences in the poster titled, "Development of an extended release nafamostat formulation for prescription drug overdose protection" at the American Association of Pharmaceutical Scientists (AAPS) 2023 PharmSci 360 event on Wednesday, October 25, 2023, in Orlando, FL.

The AAPS PharmSci 360 event highlights the end-to-end drug discovery and development process through five detailed tracks from Discovery and Basic Research through Manufacturing, Formulation and Delivery. The poster will feature the translational development of Ensysce's PF614-MPAR for treatment of severe pain, designed to prevent both abuse and overdose.

"We are thrilled to have Dr. Jacobs present the collective work of Ensysce and Quotient Sciences showcasing the groundbreaking progress in the development of PF614-MPAR, our opioid pain medication with overdose protection," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. "The AAPS PharmSci 360 event is a unique opportunity to present the Translational Pharmaceutics Platform of Quotient which Ensysce successfully used for the development of what we believe is the first opioid product with oral overdose protection. This event attracts a broad audience of industry experts and leaders, and we hope they share our enthusiasm for this transformational treatment in the battle against opioid abuse and overdose."

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP^TM) and Multi-Pill Abuse Resistance (MPAR) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.